game on

Houston esports company to provide software for a first-of-its-kind collegiate tournament

Houston-based Mainline is providing the tournament software for an unprecedented esports showdown between the Big 12 schools. Jamie McInall/Pexels

While college football's fate this fall is up in the air thanks to the coronavirus pandemic, the Big 12 Conference is definitely going to face off virtually thanks to esports software developed in Houston.

According to an announcement from the Big 12 Conference and Learfield IMG College, its multimedia rights partner, the tournament has opened for registration for all 10 member schools — Baylor University, Texas Christian University, University of Texas, Texas Tech University, Iowa State University, University of Kansas, Kansas State University, University of Oklahoma, Oklahoma State University, and West Virginia University.

"This is a great opportunity to engage in an emerging space on a Conference-wide level," says Big 12 Commissioner Bob Bowlsby in a news release. "This opportunity is a unique way to provide original content from within a competitive environment during these challenging times. We appreciate the collaborative efforts that have made this first-of-its-kind Big 12 Championship tournament possible."

Houston-based Mainline, an esports software startup, has been selected to provide the tournament software for this unprecedented event, which is set to take place July 13 to 16. Each of the 10 schools will host its own single-elimination qualifying tournament featuring Madden NFL 20. Students have until July 10 to register to compete. Big 12 Now on ESPN+ will air both the schools' finals and the Big 12 Conference Championship tournament. The host of Big 12 This Week, Bill Pollock, will call the tournament.

Not only will Mainline's tournament software enable the competition, but it will allow Learfield IMG College to sell sponsors on esports visibility. Just like the football season, the esports tournaments will promote school branding and an opportunity to connect with student participants.

"It's more important now than ever to provide college students the ability to stay connected and engaged, and our technology can help aggregate the college esports community to help make that happen," says Chris Buckner, Mainline's CEO and founder, in the release. "This will multiply the opportunity, power and fun of esports to college students attending all Big 12 universities and keeps students competing while still practicing social distancing."

Earlier this month, Buckner joined InnovationMap's Houston Innovators Podcast to discuss the opportunities — as well as the challenges — the pandemic posed for his company.

"Everyone is looking for how to get sports, or esports, in front of people because everyone is just missing [sports] so much," Buckner says on the episode. "Our June will pretty much be the best month of our company, and a lot of that is driven by the fact that everyone is looking for a digital solution rather than an in-person solution."

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted